| Loricia Lea Jenkins, CRNA | |
|
1209 Nw North Ridge Drive, Suite B, Anesthesia Services Of Blue Springs, Blue Springs, MO 64014-6320 | |
| (816) 988-8415 | |
| (816) 988-8395 |
| Full Name | Loricia Lea Jenkins |
|---|---|
| Gender | Female |
| Speciality | Nurse Anesthetist, Certified Registered |
| Location | 1209 Nw North Ridge Drive, Suite B, Blue Springs, Missouri |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821214438 | NPI | - | NPPES |
| 915473904 | Medicaid | MO | |
| P00430884 | Other | KS | RAILROAD MEDICARE |
| 200504010A | Medicaid | KS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 55593 (Kansas) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | 2007012542 (Missouri) | Primary |
| Entity Name | Anesthesia Associates Of Kansas City Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174504732 PECOS PAC ID: 1951206168 Enrollment ID: O20031201000810 |
News Archive
Archer Biosciences, Inc. announced that the trial of its novel, proprietary drug TPI-287 (an abeotaxane) for the treatment of metastatic melanoma has initiated a third drug-escalation cohort. The primary objective of this study is to determine the safety, tolerability and maximum tolerated dose (MTD) of TPI-287 in combination with temozolomide (TMZ) in adult patients with metastatic melanoma.
New research from Mass General Cancer Center, published in the June 2020 issue of JNCCN-Journal of the National Comprehensive Cancer Network, found 40.2% of hospitalized patients with advanced, incurable cancer were functionally impaired at the time of admission, meaning they needed assistance with activities of daily living (ADLs) like walking, bathing, getting dressed, or other routine tasks. Patients with functional impairment also had higher rates of pain, depression, and anxiety, and were more likely to have longer hospital stays and worse survival.
Artisan Pharma, Inc., a private biopharmaceutical company dedicated to bringing best-in-class critical care therapeutics to patients, today announced the completion of patient enrollment in its Phase 2b study of ART-123 (Recomodulin® - recombinant human thrombomodulin) in sepsis patients with disseminated intravascular coagulation (DIC). The clinical trial was a randomized, double-blind, placebo-controlled Phase 2b study to assess the safety and efficacy of ART-123 in patients with sepsis and DIC.
Higher rates of severe COVID-19 infections in Black, Asian and Minority Ethnic (BAME) populations are not explained by socioeconomic or behavioral factors, cardiovascular disease risk, or by vitamin D status, according to new research led by Queen Mary University of London.
Omeros Corporation today reported analyses of Phase 3 clinical data showing the impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement. OMS302 is the company's proprietary Pharmacosurgery product being developed for all ILR, including cataract surgery and refractive lens exchange.
› Verified 3 days ago
| Entity Name | Meritas Health Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801875091 PECOS PAC ID: 6305748153 Enrollment ID: O20040122001058 |
News Archive
Archer Biosciences, Inc. announced that the trial of its novel, proprietary drug TPI-287 (an abeotaxane) for the treatment of metastatic melanoma has initiated a third drug-escalation cohort. The primary objective of this study is to determine the safety, tolerability and maximum tolerated dose (MTD) of TPI-287 in combination with temozolomide (TMZ) in adult patients with metastatic melanoma.
New research from Mass General Cancer Center, published in the June 2020 issue of JNCCN-Journal of the National Comprehensive Cancer Network, found 40.2% of hospitalized patients with advanced, incurable cancer were functionally impaired at the time of admission, meaning they needed assistance with activities of daily living (ADLs) like walking, bathing, getting dressed, or other routine tasks. Patients with functional impairment also had higher rates of pain, depression, and anxiety, and were more likely to have longer hospital stays and worse survival.
Artisan Pharma, Inc., a private biopharmaceutical company dedicated to bringing best-in-class critical care therapeutics to patients, today announced the completion of patient enrollment in its Phase 2b study of ART-123 (Recomodulin® - recombinant human thrombomodulin) in sepsis patients with disseminated intravascular coagulation (DIC). The clinical trial was a randomized, double-blind, placebo-controlled Phase 2b study to assess the safety and efficacy of ART-123 in patients with sepsis and DIC.
Higher rates of severe COVID-19 infections in Black, Asian and Minority Ethnic (BAME) populations are not explained by socioeconomic or behavioral factors, cardiovascular disease risk, or by vitamin D status, according to new research led by Queen Mary University of London.
Omeros Corporation today reported analyses of Phase 3 clinical data showing the impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement. OMS302 is the company's proprietary Pharmacosurgery product being developed for all ILR, including cataract surgery and refractive lens exchange.
› Verified 3 days ago
| Entity Name | Heartland Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477575405 PECOS PAC ID: 6709772767 Enrollment ID: O20040225001201 |
News Archive
Archer Biosciences, Inc. announced that the trial of its novel, proprietary drug TPI-287 (an abeotaxane) for the treatment of metastatic melanoma has initiated a third drug-escalation cohort. The primary objective of this study is to determine the safety, tolerability and maximum tolerated dose (MTD) of TPI-287 in combination with temozolomide (TMZ) in adult patients with metastatic melanoma.
New research from Mass General Cancer Center, published in the June 2020 issue of JNCCN-Journal of the National Comprehensive Cancer Network, found 40.2% of hospitalized patients with advanced, incurable cancer were functionally impaired at the time of admission, meaning they needed assistance with activities of daily living (ADLs) like walking, bathing, getting dressed, or other routine tasks. Patients with functional impairment also had higher rates of pain, depression, and anxiety, and were more likely to have longer hospital stays and worse survival.
Artisan Pharma, Inc., a private biopharmaceutical company dedicated to bringing best-in-class critical care therapeutics to patients, today announced the completion of patient enrollment in its Phase 2b study of ART-123 (Recomodulin® - recombinant human thrombomodulin) in sepsis patients with disseminated intravascular coagulation (DIC). The clinical trial was a randomized, double-blind, placebo-controlled Phase 2b study to assess the safety and efficacy of ART-123 in patients with sepsis and DIC.
Higher rates of severe COVID-19 infections in Black, Asian and Minority Ethnic (BAME) populations are not explained by socioeconomic or behavioral factors, cardiovascular disease risk, or by vitamin D status, according to new research led by Queen Mary University of London.
Omeros Corporation today reported analyses of Phase 3 clinical data showing the impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement. OMS302 is the company's proprietary Pharmacosurgery product being developed for all ILR, including cataract surgery and refractive lens exchange.
› Verified 3 days ago
| Entity Name | Outpatient Anesthesia Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194828673 PECOS PAC ID: 8325930803 Enrollment ID: O20040329000795 |
News Archive
Archer Biosciences, Inc. announced that the trial of its novel, proprietary drug TPI-287 (an abeotaxane) for the treatment of metastatic melanoma has initiated a third drug-escalation cohort. The primary objective of this study is to determine the safety, tolerability and maximum tolerated dose (MTD) of TPI-287 in combination with temozolomide (TMZ) in adult patients with metastatic melanoma.
New research from Mass General Cancer Center, published in the June 2020 issue of JNCCN-Journal of the National Comprehensive Cancer Network, found 40.2% of hospitalized patients with advanced, incurable cancer were functionally impaired at the time of admission, meaning they needed assistance with activities of daily living (ADLs) like walking, bathing, getting dressed, or other routine tasks. Patients with functional impairment also had higher rates of pain, depression, and anxiety, and were more likely to have longer hospital stays and worse survival.
Artisan Pharma, Inc., a private biopharmaceutical company dedicated to bringing best-in-class critical care therapeutics to patients, today announced the completion of patient enrollment in its Phase 2b study of ART-123 (Recomodulin® - recombinant human thrombomodulin) in sepsis patients with disseminated intravascular coagulation (DIC). The clinical trial was a randomized, double-blind, placebo-controlled Phase 2b study to assess the safety and efficacy of ART-123 in patients with sepsis and DIC.
Higher rates of severe COVID-19 infections in Black, Asian and Minority Ethnic (BAME) populations are not explained by socioeconomic or behavioral factors, cardiovascular disease risk, or by vitamin D status, according to new research led by Queen Mary University of London.
Omeros Corporation today reported analyses of Phase 3 clinical data showing the impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement. OMS302 is the company's proprietary Pharmacosurgery product being developed for all ILR, including cataract surgery and refractive lens exchange.
› Verified 3 days ago
| Entity Name | Midwest Digestive Health Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821324260 PECOS PAC ID: 4587601497 Enrollment ID: O20091203000735 |
News Archive
Archer Biosciences, Inc. announced that the trial of its novel, proprietary drug TPI-287 (an abeotaxane) for the treatment of metastatic melanoma has initiated a third drug-escalation cohort. The primary objective of this study is to determine the safety, tolerability and maximum tolerated dose (MTD) of TPI-287 in combination with temozolomide (TMZ) in adult patients with metastatic melanoma.
New research from Mass General Cancer Center, published in the June 2020 issue of JNCCN-Journal of the National Comprehensive Cancer Network, found 40.2% of hospitalized patients with advanced, incurable cancer were functionally impaired at the time of admission, meaning they needed assistance with activities of daily living (ADLs) like walking, bathing, getting dressed, or other routine tasks. Patients with functional impairment also had higher rates of pain, depression, and anxiety, and were more likely to have longer hospital stays and worse survival.
Artisan Pharma, Inc., a private biopharmaceutical company dedicated to bringing best-in-class critical care therapeutics to patients, today announced the completion of patient enrollment in its Phase 2b study of ART-123 (Recomodulin® - recombinant human thrombomodulin) in sepsis patients with disseminated intravascular coagulation (DIC). The clinical trial was a randomized, double-blind, placebo-controlled Phase 2b study to assess the safety and efficacy of ART-123 in patients with sepsis and DIC.
Higher rates of severe COVID-19 infections in Black, Asian and Minority Ethnic (BAME) populations are not explained by socioeconomic or behavioral factors, cardiovascular disease risk, or by vitamin D status, according to new research led by Queen Mary University of London.
Omeros Corporation today reported analyses of Phase 3 clinical data showing the impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement. OMS302 is the company's proprietary Pharmacosurgery product being developed for all ILR, including cataract surgery and refractive lens exchange.
› Verified 3 days ago
| Entity Name | Mosaic Medical Center - Maryville |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184189797 PECOS PAC ID: 3678813896 Enrollment ID: O20190405001537 |
News Archive
Archer Biosciences, Inc. announced that the trial of its novel, proprietary drug TPI-287 (an abeotaxane) for the treatment of metastatic melanoma has initiated a third drug-escalation cohort. The primary objective of this study is to determine the safety, tolerability and maximum tolerated dose (MTD) of TPI-287 in combination with temozolomide (TMZ) in adult patients with metastatic melanoma.
New research from Mass General Cancer Center, published in the June 2020 issue of JNCCN-Journal of the National Comprehensive Cancer Network, found 40.2% of hospitalized patients with advanced, incurable cancer were functionally impaired at the time of admission, meaning they needed assistance with activities of daily living (ADLs) like walking, bathing, getting dressed, or other routine tasks. Patients with functional impairment also had higher rates of pain, depression, and anxiety, and were more likely to have longer hospital stays and worse survival.
Artisan Pharma, Inc., a private biopharmaceutical company dedicated to bringing best-in-class critical care therapeutics to patients, today announced the completion of patient enrollment in its Phase 2b study of ART-123 (Recomodulin® - recombinant human thrombomodulin) in sepsis patients with disseminated intravascular coagulation (DIC). The clinical trial was a randomized, double-blind, placebo-controlled Phase 2b study to assess the safety and efficacy of ART-123 in patients with sepsis and DIC.
Higher rates of severe COVID-19 infections in Black, Asian and Minority Ethnic (BAME) populations are not explained by socioeconomic or behavioral factors, cardiovascular disease risk, or by vitamin D status, according to new research led by Queen Mary University of London.
Omeros Corporation today reported analyses of Phase 3 clinical data showing the impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement. OMS302 is the company's proprietary Pharmacosurgery product being developed for all ILR, including cataract surgery and refractive lens exchange.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Loricia Lea Jenkins, CRNA 25012 W. 86th Terrace, Lenexa, KS 66227-3522 Ph: (316) 304-3144 | Loricia Lea Jenkins, CRNA 1209 Nw North Ridge Drive, Suite B, Anesthesia Services Of Blue Springs, Blue Springs, MO 64014-6320 Ph: (816) 988-8415 |
News Archive
Archer Biosciences, Inc. announced that the trial of its novel, proprietary drug TPI-287 (an abeotaxane) for the treatment of metastatic melanoma has initiated a third drug-escalation cohort. The primary objective of this study is to determine the safety, tolerability and maximum tolerated dose (MTD) of TPI-287 in combination with temozolomide (TMZ) in adult patients with metastatic melanoma.
New research from Mass General Cancer Center, published in the June 2020 issue of JNCCN-Journal of the National Comprehensive Cancer Network, found 40.2% of hospitalized patients with advanced, incurable cancer were functionally impaired at the time of admission, meaning they needed assistance with activities of daily living (ADLs) like walking, bathing, getting dressed, or other routine tasks. Patients with functional impairment also had higher rates of pain, depression, and anxiety, and were more likely to have longer hospital stays and worse survival.
Artisan Pharma, Inc., a private biopharmaceutical company dedicated to bringing best-in-class critical care therapeutics to patients, today announced the completion of patient enrollment in its Phase 2b study of ART-123 (Recomodulin® - recombinant human thrombomodulin) in sepsis patients with disseminated intravascular coagulation (DIC). The clinical trial was a randomized, double-blind, placebo-controlled Phase 2b study to assess the safety and efficacy of ART-123 in patients with sepsis and DIC.
Higher rates of severe COVID-19 infections in Black, Asian and Minority Ethnic (BAME) populations are not explained by socioeconomic or behavioral factors, cardiovascular disease risk, or by vitamin D status, according to new research led by Queen Mary University of London.
Omeros Corporation today reported analyses of Phase 3 clinical data showing the impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement. OMS302 is the company's proprietary Pharmacosurgery product being developed for all ILR, including cataract surgery and refractive lens exchange.
› Verified 3 days ago
Timothy D Fundenberger, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1209 Nw North Ridge Dr Ste B, Anesthesia Services Of Blue Springs, Blue Springs, MO 64015 Phone: 816-988-8415 Fax: 816-988-8395 | |
Mr. Jeremy Michael Daves, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 201 Nw R D Mize Rd, Anesthesia Services Of Blue Springs/st. Mary's Medical, Blue Springs, MO 64014 Phone: 816-988-8415 Fax: 816-335-4003 | |
Mrs. Brenda Rae Rutherford, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 209 Nw North Ridge Drive, Suite B, Anesthesia Services Of Blue Springs, Blue Springs, MO 64015 Phone: 816-988-8415 Fax: 816-988-8395 | |
Dina Lynn Lutjen, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1209 Nw North Ridge Dr, Suite B, Blue Springs, MO 64015 Phone: 816-988-8415 Fax: 816-988-8395 | |
Denise A Wilson, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1209 Nw North Ridge Dr Ste B, Anesthesia Services Of Blue Springs, Blue Springs, MO 64015 Phone: 816-988-8415 Fax: 816-988-8395 | |
Karen L. Graybill, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1209 Nw North Ridge Dr Ste B, Anesthesia Services Of Blue Springs, Blue Springs, MO 64015 Phone: 816-988-8415 Fax: 816-988-8395 | |
Sherry J Hugi, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1209 Nw North Ridge Dr Ste B, Anesthesia Services Of Blue Springs, Blue Springs, MO 64015 Phone: 816-988-8415 Fax: 816-988-8395 |